We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
US-based research-driven biotechnology company Integral Molecular has begun a therapeutic target discovery programme in immuno-oncology by utilising its membrane proteome array technology to identify cell-surface proteins...